Actionable news
All posts from Actionable news

Marinus Pharmaceuticals’ Ganaxolone IV Demonstrates Robust Efficacy in Benzodiazepine-Resistant Model of Status Epilepticus

Data Presented at the American Academy of Neurology Annual Meeting

Phase 1 Clinical Program On-Track to Initiate in 1H 2016

RADNOR, Pa., April 19, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, presented preclinical data of ganaxolone IV, the Company's intravenous formulation of its CNS-selective GABAA modulator, showing robust activity in a well-accepted and clinically translatable animal model of status epilepticus (SE). The data were presented during an oral and poster presentations at the 68thAmerican Academy of Neurology (AAN) Annual Meeting in Vancouver, BC, Canada, April 15-21, 2016.

Albena Patroneva, M.D., Chief Medical Officer of Marinus Pharmaceuticals, commented, "Status epilepticus is a life threatening medical emergency with no FDA approved treatment. Typically, single or combination IV antiepileptic drugs are used in an attempt to break the seizures, however many patients do not respond to treatment, which increases the risk of neuronal damage, cognitive impairment and death. The preclinical data presented at AAN shows that ganaxolone IV could be a promising therapeutic for this vulnerable patient group and serves as the foundation for our clinical development plan, which is on-track to initiate a Phase 1 clinical trial this quarter."

The first abstract, entitled, "Ganaxolone administered intravenously prevents behavioral seizures and promotes survival in the rat lithium-pilocarpine model of status epilepticus," was presented by Michael S. Saporito
, Ph.D., during dual oral and poster presentations. The poster highlighted a study on ganaxolone IV in a clinically translatable rodent model of SE, in which convulsive SE was induced by the administration of lithium chloride and pilocarpine in male rats. Ganaxolone IV (6, 9, or 12 mg/kg) or allopregnanolone (15 mg/kg) were administered at the time of SE onset or 15, 30 or 60 minutes after SE onset. In this rodent model, ganaxolone IV produced a dose-dependent anticonvulsant effect at...